文献速递神经核医学核素与放射性配体治疗

神经肿瘤学中的诊疗一体化:迈向新视野

Theranostics in Neurooncology: Heading Toward New Horizons.
PubMed 文献 · J Nucl Med · 2024-02-01

脑肿瘤治疗仍面临药物递送受限的挑战,将前列腺癌和神经内分泌肿瘤中成熟的诊疗一体化方法转化至神经肿瘤学正重新受到关注。部分方法在脑膜瘤和某些儿童脑肿瘤的软脑膜播散中显示初步鼓舞性结果,但在脑转移瘤和胶质瘤中临床结果未能令人印象深刻。多数诊疗一体化药物难以跨越血脑屏障,其递送依赖于增强通透性和滞留技术的成功开发与临床实施,国际社会应努力开展足够大的随机研究以产生高级别证据。

要点

  • 脑膜瘤和某些儿童脑肿瘤软脑膜播散中,诊疗一体化方法显示初步鼓舞性结果。
  • 脑转移瘤和胶质瘤中,诊疗一体化方法的临床结果未能令人印象深刻。
  • 多数诊疗一体化药物难以跨越血脑屏障,递送依赖增强通透性和滞留技术的发展。

核心结论

  • 将诊疗一体化方法转化至神经肿瘤学正重新受到关注,部分方法在脑膜瘤和某些儿童脑肿瘤软脑膜播散中显示初步鼓舞性结果,但在脑转移瘤和胶质瘤中临床结果未能令人印象深刻。

研究设计与样本

  • 本文为综述,讨论诊疗一体化方法在脑膜瘤、脑转移瘤、胶质瘤和常见儿童脑肿瘤中的背景、文献概览和未来展望,正在进行的研究在补充材料中讨论。

主要发现

  • 脑膜瘤和某些儿童脑肿瘤的软脑膜播散中,部分诊疗一体化方法显示初步鼓舞性结果。
  • 脑转移瘤和胶质瘤中,诊疗一体化方法的临床结果未能令人印象深刻。
  • 多数诊疗一体化药物不太可能跨越血脑屏障,其递送将依赖于增强通透性和滞留技术的成功开发与临床实施。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出多数诊疗一体化药物不太可能跨越血脑屏障,其递送将依赖于增强通透性和滞留技术的成功开发与临床实施。
  • 原文指出国际社会应努力开展足够大的随机研究,以产生中枢神经系统肿瘤放射性配体诊疗一体化方法的高级别证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic approaches to brain tumors remain a challenge, with considerable limitations regarding delivery of drugs. There has been renewed and increasing interest in translating the popular theranostic approach well known from prostate and neuroendocrine cancer to neurooncology. Although far from perfect, some of these approaches show encouraging preliminary results, such as for meningioma and leptomeningeal spread of certain pediatric brain tumors. In brain metastases and gliomas, clinical results have failed to impress. Perspectives on these theranostic approaches regarding meningiomas, brain metastases, gliomas, and common pediatric brain tumors will be discussed. For each tumor entity, the general context, an overview of the literature, and future perspectives will be provided. Ongoing studies will be discussed in the supplemental materials. As most theranostic agents are unlikely to cross the blood-brain barrier, the delivery of these agents will be dependent on the successful development and clinical implementation of techniques enhancing permeability and retention. Moreover, the international community should strive toward sufficiently large and randomized studies to generate high-level evidence on theranostic approaches with radioligand therapies for central nervous system tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tolboom N, Verger A, Albert NL, et al. Theranostics in Neurooncology: Heading Toward New Horizons. J Nucl Med. 2024. PMID: 38071569. doi:10.2967/jnumed.123.266205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。